Sepsis, phages, and covid‐19

Abstract

Phage therapy has emerged as a potential novel treatment of sepsis for which no decisive progress has been achieved thus far. Obviously, phages can help eradicate local bacterial infection and bacteremia that may occur in a syndrome. For example, phages may be helpful in correcting excessive inflammatory responses and aberrant immunity that occur in sepsis. Data from animal studies strongly suggest that phages may indeed be an efficient means of therapy for experimentally induced sepsis. In recent years, a number of reports have appeared describing the successful treatment of patients with sepsis. Moreover, novel data on the anti‐viral potential of phages may be interpreted as suggesting that phages could be used as an adjunct therapy in severe COVID‐19. Thus, clinical trials assessing the value of phage therapy in sepsis, including viral sepsis, are urgently needed.